RE:RE:RE:Fast Track + PR (CR) = Accelerated ApprovalFurthermore, the potential of an accelerated approval for pelareorep in the pancreatic cancer indication is a significant advantage in ONCY's negotiations with a potential acquirer of the company and can be a postive leverage in the overall process, now that we have seen the Goblet results in this cohort of patients.
Both of the Big Pharma players (Pfizer/Merck KGaA) in the Bracelet-1 study know what the yet-to-be-made-public results are, and the recent pancreatic cancer results from the Goblet study should be enough for them to move on what we are seeking.